Twist Bioscience
TWST
235 hedge funds and large institutions have $5.2B invested in Twist Bioscience in 2021 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 95 increasing their positions, 57 reducing their positions, and 38 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 57
57% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $11.1M
0.29% more ownership
Funds ownership: 98.43% → 98.72% (+0.29%)
4% less funds holding
Funds holding: 244 → 235 (-9)
18% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 38
19% less capital invested
Capital invested by funds: $6.4B → $5.2B (-$1.2B)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
Top Sellers
TWST Hedge Fund Activity: Q3 2021 in Review
235 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q3 2021, worth a combined $5.2B — down 19% from $6.4B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TWST and 31 opened new positions — a net loss of 7 holders — while 57 trimmed existing stakes and 95 added.
The largest buyer was Fidelity Investments, adding an estimated $178M. The largest seller was ARK Investment Management, cutting an estimated $127M.
- 235 institutional investors held Twist Bioscience (TWST) as of Q3 2021, down from 244 in Q2 2021.
- Funds reported $5.2B of Twist Bioscience stock for Q3 2021, down 19% quarter-over-quarter.
- 31 funds opened new Twist Bioscience positions in Q3 2021 and 38 closed out, a net change of -7 holders.
- The largest Twist Bioscience buyer in Q3 2021 was Fidelity Investments, an estimated $178M added.
- The largest Twist Bioscience seller in Q3 2021 was ARK Investment Management, an estimated $127M sold.
Based on aggregated 13F filings for Q3 2021.